Maria-Lorena Mustata

Dr. Maria-Lorena Mustata

University of Medicine and Pharmacy of Craiova, Craiova, Dolj, Romania
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
RARoxana Viorela Ahritculesei
Roxana Viorela Ahritculesei
BLBOLDEANU LIDIA
BOLDEANU LIDIA
IVIonela Mihaela Vladu
Ionela Mihaela Vladu
Diana ClenciuDiana Clenciu
Diana Clenciu
AMADINA MITREA
ADINA MITREA
CVCristin Constantin Vere
Cristin Constantin Vere
Background/Objectives: The prognostic nutritional index (PNI) and Glasgow Prognostic Score (GPS) are associated with patients’ nutritional and immune statuses. One important factor in the pathophysiology of type 2 diabetes mellitus (T2DM) is inflammation. Being present in insulin-target tissues, chronic tissue inflammation has become recognized as a crucial aspect of obesity and type 2 diabetes. This study aimed to compare the PNI and GPS levels of the subjects with T2DM to those of prediabetes (preDM) individuals. Furthermore, the goal was to investigate how these inflammatory markers relate to different types of obesity and whether the combination of PNI, GPS, and obesity-related indices was associated with any particular prognostic variables. Methods: In this study, we enrolled one-hundred patients with newly diagnosed T2DM and one-hundred patients with preDM. Results: Four findings emerged from this observational study. As a first observation, 28% of patients with preDM and 15% of patients with T2DM had a normal weight, while up to 43% of patients with preDM and 60% of patients with T2DM were obese. The second important observation was that the PNI of the T2DM patients was significantly lower than the PNI of the patients with preDM (p < 0.0001). The PNI showed that patients with T2DM had a moderate-to-severe malnutrition status (median value of 38.00). Patients with preDM had a mild-to-moderate malnutrition status (median value of 61.00) at diagnosis. Third, observed in the current study, preDM patients with PNI < 61.00 and T2DM patients with a PNI < 38.00 were associated with significantly higher median values of the waist-to-height ratio (WHtR) (p = 0.041, and p = 0.034, respectively) and body mass index (BMI) (p = 0.016, and p = 0.041, respectively). Fourth, this study also revealed, in the T2DM group, a moderate and statistically significant negative correlation between PNI and weight (rho = −0.322, p = 0.035), waist circumference (WC) (rho = −0.308, p = 0.042), hip circumference (HC) (rho = −0.338, p = 0.039), WHtR (rho = −0.341, p = 0.022), body adiposity index (BAI) (rho = −0.312, p = 0.032), and fasting plasma glucose (FPG) (rho = −0.318, p = 0.029). Additionally, the PNI values expressed a weak negative correlation with BMI (rho = −0.279, p = 0.015), and glycated hemoglobin A1c (HbA1c) (rho = −0.245, p = 0.025). The PNI levels exhibited a single positive correlation, weak but statistically significant, with estimated glomerular filtration rate (eGFR-CKD-EPI) values (rho = 0.263, p = 0.018). Conclusions: The findings of this study regarding the correlations between PNI, GPS, and different obesity-related indices in people with diabetes or prediabetes suggest that these indices, which assess nutritional and inflammatory status, can be used as independent predictor factors associated with the four pillars of DM management (glucose, blood pressure, lipids, and weight control) recommended by the American Diabetes Association (ADA).

31 January 2025 in Life
Verified
Journal Article
Open access
PDF file
Maria-Lorena MustataMaria-Lorena Mustata
Maria-Lorena Mustata
CNCarmen Daniela Neagoe
Carmen Daniela Neagoe
Virginia Maria RadulescuVirginia Maria Radulescu
Virginia Maria Radulescu
IDIoana-Gabriela Dragne
Ioana-Gabriela Dragne
RCRadu Cristian Cimpeanu
Radu Cristian Cimpeanu
Simona Laura IanoșiSimona Laura Ianoși
Simona Laura Ianoși
Background/objectives: Psoriasis is a chronic inflammatory autoimmune disease with important systemic and psychosocial impacts. The association with metabolic syndrome (MS) impairs disease severity and negatively influences patient-reported outcomes, particularly their quality of life as measured by the Dermatology Life Quality Index (DLQI). This study aims to investigate the relationship between systemic inflammation, DLQI scores and disease severity, focusing on the persistent impact of MS on patient outcomes after one year of treatment. Methods: This retrospective cross-sectional study included 150 psoriasis patients, with 74 also meeting the diagnostic criteria for MS. Clinical and inflammatory markers such as systemic immune–inflammatory index (SII), cytokines (IL-17A, IL-23), leptin, BMI and triglycerides were analyzed alongside PASI and DLQI scores. Results: Patients with MS had significantly higher PASI and DLQI scores compared to those without MS, reflecting worse disease severity and quality of life (p < 0.01). Elevated SII levels were strongly associated with higher DLQI scores (p < 0.01). Despite considerable reductions in PASI scores over one year of treatment, DLQI scores indicated a persistent negative impact of MS on quality of life. Notably, markers of systemic inflammation, such as SII, leptin and cytokines, correlated positively with both PASI and DLQI scores, highlighting the role of systemic inflammation in disease burden. Conclusions: This study underlines the significant role of systemic inflammation and metabolic comorbidities in amplifying the burden of psoriasis. The persistent impact of MS on quality of life despite clinical improvement underscores the need for comprehensive treatment approaches targeting systemic inflammation, metabolic health and psychosocial factors to improve long-term outcomes.

14 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Maria-Lorena MustataMaria-Lorena Mustata
Maria-Lorena Mustata
CNCarmen Daniela Neagoe
Carmen Daniela Neagoe
MIMihaela Ionescu
Mihaela Ionescu
MPMaria-Cristina Predoi
Maria-Cristina Predoi
AMAna-Maria Mitran
Ana-Maria Mitran
Simona Laura IanoșiSimona Laura Ianoși
Simona Laura Ianoși
Psoriasis is an increasingly common chronic immune-mediated skin disease recognized for its systemic effects that extend beyond the skin and include various cardiovascular diseases, neurological diseases, type 2 diabetes, and metabolic syndrome. This study aimed to explore the complex relationship between psoriasis and metabolic syndrome by analyzing clinical, biochemical, and immunological parameters in patients with psoriasis alone and in patients combining psoriasis and metabolic syndrome. A total of 150 patients were enrolled, 76 with psoriasis only (PSO) and 74 with psoriasis and metabolic syndrome (PSO–MS). Data collected included anthropometric measurements, blood tests, and inflammatory markers. Statistical analysis was performed using the independent t-test, Mann–Whitney U test, Kruskal–Wallis test, and chi-square test to compare the two groups. Patients in the PSO–MS group had a significantly higher body weight, abdominal circumference, BMI, and inflammatory markers compared to patients with PSO. In addition, increased levels of IL-17A, cholesterol, triglycerides, and glucose were observed in the PSO–MS group. This study highlights the increased metabolic risk and exacerbated systemic inflammation associated with the coexistence of psoriasis and metabolic syndrome. These findings demonstrate the need for a comprehensive therapeutic approach and early intervention to manage metabolic complications in patients with psoriasis and metabolic syndrome.

3 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Maria-Lorena MustataMaria-Lorena Mustata
Maria-Lorena Mustata
CNCarmen Daniela Neagoe
Carmen Daniela Neagoe
Virginia Maria RadulescuVirginia Maria Radulescu
Virginia Maria Radulescu
IDIoana-Gabriela Dragne
Ioana-Gabriela Dragne
RCRadu Cristian Cimpeanu
Radu Cristian Cimpeanu
Simona Laura IanoșiSimona Laura Ianoși
Simona Laura Ianoși
Background/Objectives: Psoriasis is a chronic inflammatory autoimmune disease with important systemic and psychosocial impacts. The association with metabolic syndrome (MS) impairs disease severity and negatively influences patient-reported outcomes, particularly their quality of life as measured by the Dermatology Life Quality Index (DLQI). This study aims to investigate the relationship between systemic inflammation, DLQI scores, and disease severity, focusing on the persistent impact of MS on patient outcomes after one year of treatment. Methods: This retrospective cross-sectional study included 150 psoriasis patients, with 74 also meeting the diagnostic criteria for MS. Clinical and inflammatory markers such as systemic immune-inflammatory index (SII), cytokines (IL-17A, IL-23), leptin, BMI, and triglycerides were analyzed alongside PASI and DLQI scores. Results: Patients with MS had significantly higher PASI and DLQI scores compared to those without MS, reflecting worse disease severity and quality of life (p < 0.001). Elevated SII levels were strongly associated with higher DLQI scores (p < 0.0001). Despite considerable reductions in PASI scores over one year of treatment, DLQI scores indicated a persistent negative impact of MS on quality of life. Notably, markers of systemic inflammation, such as SII, leptin, and cytokines, correlated positively with both PASI and DLQI scores, highlighting the role of systemic inflammation in disease burden. Conclusions: This study underlines the significant role of systemic inflammation and metabolic comorbidities in amplifying the burden of psoriasis. The persistent impact of MS on quality of life despite clinical improvement underscores the need for comprehensive treatment approaches targeting systemic inflammation, metabolic health, and psychosocial factors to improve long-term outcomes.

23 December 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Maria-Lorena MustataMaria-Lorena Mustata
Maria-Lorena Mustata
MIMihaela Ionescu
Mihaela Ionescu
LRLucretiu Radu
Lucretiu Radu
CNCarmen Daniela Neagoe
Carmen Daniela Neagoe
RARoxana Viorela Ahritculesei
Roxana Viorela Ahritculesei
Simona Laura IanoșiSimona Laura Ianoși
Simona Laura Ianoși
Background/Objectives: Psoriasis is a chronic dermatological condition with systemic implications, especially with metabolic syndrome (MS). This study evaluated the vicious cycle where obesity and MS exacerbate systemic inflammation that complicates the efficacy of psoriasis therapies by examining the PASI score over a one-year period. Patients were classified into two subgroups: those with psoriasis alone (PSO) and those with both psoriasis and metabolic syndrome (PSO-MS). Methods: A total of 150 patients, half of whom also concomitantly presented with metabolic syndrome, received biologic therapies comprising anti-IL-17, anti-IL-23, and anti-TNF-a, or methotrexate, with PASI scores assessed at baseline and at 3, 6, and 12 months. Results: All treatments showed significant reductions in PASI; however, patients with PSO showed more marked reductions in PASI score than those in the PSO-MS group. Anti-IL-17 treatments produced the greatest sustained long-term improvements, whereas anti-IL-23 produced prompt early improvements. Increases in BMI and leptin concentrations were associated with a modest rate of reduction in PASI score, underlining the impact of obesity and metabolic dysfunction on treatment efficacy. Conclusions: This study highlights the importance of managing comorbidities such as MS in the treatment of psoriasis, as the interplay between systemic inflammation and metabolic health further complicates therapeutic outcomes.

17 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
VAVieru Alexandru
Vieru Alexandru
Virginia Maria RadulescuVirginia Maria Radulescu
Virginia Maria Radulescu
ETEmil Tiberius Traşcă
Emil Tiberius Traşcă
SCSergiu Marian Cazacu
Sergiu Marian Cazacu
Maria-Lorena MustataMaria-Lorena Mustata
Maria-Lorena Mustata
CTCiurea Tudorel
Ciurea Tudorel
Background/Objectives: The COVID-19 pandemic disrupted healthcare delivery worldwide, potentially delaying the diagnosis and treatment of oncologic diseases. This study aimed to evaluate the impact of the pandemic on stage at diagnosis, treatment allocation, and survival outcomes among patients with gastric cancer. Methods: We retrospectively analyzed 419 consecutive patients diagnosed with gastric cancer between January 2018 and December 2021 at a tertiary oncology–surgical center. Patients were divided into pre-pandemic (2018–2019) and pandemic (2020–2021) cohorts. Demographic, clinical, and treatment variables were compared using t-tests and χ2 tests. Multivariate logistics and Cox regression models were applied to identify independent predictors of metastatic presentation and mortality. Overall survival (OS) was calculated from diagnosis to death or last contact (OS_days), with same-day events censored at time zero. Results: Baseline characteristics were comparable between cohorts (age, p = 0.098; sex, p = 0.137; residence, p = 0.345). The proportion of metastatic cases (M1) increased from 42.8% in 2018–2019 to 64.4% in 2020–2021 (χ2 p < 0.001). Surgical rates remained stable (55.1% vs. 47.7%, p = 0.161). Diagnosis during the pandemic independently predicted metastatic presentation (OR = 2.63, 95% CI 1.68–4.11, p < 0.001) and higher mortality (HR = 1.72, 95% CI 1.41–2.03, p < 0.001). Kaplan–Meier analysis confirmed significantly reduced OS in the pandemic cohort (log-rank χ2 = 81.29, p < 0.001). Conclusions: The pandemic was associated with delayed diagnosis, stage migration toward advanced disease, and inferior survival in gastric cancer, despite comparable demographics and treatment capacity. These findings emphasize the need to safeguard diagnostic pathways—particularly endoscopy—during healthcare crises to prevent avoidable oncologic deterioration.